“CytoDyn will soon receive results from a preclinical study of leronlimab in a mouse model of MASH. That study is meant to clarify the correct dosing of leronlimab in the MASH setting and address the question of potential synergy with Resmetirom, the only currently approved therapy for the treatment of MASH.“

Anyone else looking forward to this? If the results are good this could mean a phase 3 combo with their company?

This could be a big deal.